Gandjour, Afschin; Schüßler, Sofia; Hammerschmidt, Thomas - In: The European Journal of Health Economics 21 (2020) 7, pp. 1049-1057
Introduction In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of...